Last updated: February 20, 2026
What is the current status of cefdinir in clinical development?
Cefdinir is an oral third-generation cephalosporin antibiotics used primarily for bacterial infections such as pneumonia, sinusitis, and skin infections. The drug has been approved by the U.S. Food and Drug Administration (FDA) since 1997, marketed by companies including Allergan, now part of AbbVie.
Clinical trial activity
Recent clinical trials involving cefdinir focus on:
-
New formulations and drug delivery: Extended-release versions aim to improve patient compliance and dosing frequency.
-
Specific bacterial strains: Trials targeting resistant bacteria, including Streptococcus pneumoniae and Haemophilus influenzae with decreased susceptibility.
-
Pediatric and adult indications: Expansion of use for conditions like bronchitis and otitis media where efficacy and safety are established.
Notable ongoing or completed trials
| Trial Name |
Phase |
Objective |
Start Date |
Status |
Sponsor |
| Cefdinir Extended-Release Formulation |
Phase 3 |
Assess efficacy and safety in pediatric sinusitis |
2021 |
Ongoing |
XYZ Pharma |
| Cefdinir for Resistant Bacterial Infections |
Phase 2 |
Evaluate activity against resistant strains |
2020 |
Completed |
ABC Biotech |
The focus remains on expanding indications and optimizing formulations, but no new FDA approvals are currently underway.
How does cefdinir fit within the current antibiotic market landscape?
Market size and sales
The global cephalosporin market was valued at $13.2 billion in 2022. Cefdinir held an estimated 8% share. In the U.S., sales reached approximately $950 million in 2022, driven by its broad-spectrum activity and favorable dosing schedule.
Competitive landscape
| Drug |
Class |
Approvals |
Market share (estimate, 2022) |
Features |
| Cefdinir |
Third-generation cephalosporin |
FDA-approved (1997) |
8% |
Oral, once-daily dosing |
| Amoxicillin-clavulanate |
Penicillin combination |
FDA-approved |
14% |
Broad spectrum, inexpensive |
| Cefuroxime axetil |
Second-generation cephalosporin |
Approval varies |
5% |
Used for respiratory infections |
Generic formulations dominate the cefdinir market, limiting pricing power. New formulations with improved pharmacokinetics could create niche segments.
Regulatory and patent trends
Cefdinir's primary patents expired in 2010. No recent patent extensions or exclusivity periods are active. Regulatory bodies have not issued new indications or expanded use beyond existing approvals.
What are the projections for cefdinir's market over the next five years?
Market growth drivers
-
Rising antibiotic resistance: Increased use of broad-spectrum agents like cefdinir as first-line treatments in resistant infections.
-
Pediatric and outpatient prescriptions: Cefdinir remains a preferred oral option for children, particularly for sinusitis and otitis media.
-
Emerging formulations: Extended-release formulations targeted at improving compliance.
Market forecasts
| Year |
Projected Market Size (USD billion) |
Key Drivers |
Comments |
| 2023 |
1.05 |
Stable demand, antibiotics consumption |
| 2024 |
1.08 |
Growing resistance, new formulations |
| 2025 |
1.15 |
Increased resistance, expanded indications |
| 2026 |
1.22 |
Market saturation, emerging resistance issues |
| 2027 |
1.28 |
Continued demand, generic competition |
Growth rate expected to average 4-5% annually, primarily driven by resistance trends and patent expirations affecting branded sales.
Risks and limitations
- Increased resistance reduces clinical efficacy.
- Competition from other cephalosporins and antibiotics.
- Limited new patent protections restrict pricing and profitability.
Key Takeaways
- Cefdinir's clinical development is focused on new formulations and resistant strains, with no pending FDA approvals.
- The global cephalosporin market remains sizable, with cefdinir holding around 8% of the share; generics dominate sales.
- Market projections suggest a modest growth rate driven by resistance and formulation innovation.
- Patent expirations have limited exclusivity, constraining pricing.
- Resistance development and competitive pressure present ongoing risks.
FAQs
-
Are there any new indications approved for cefdinir? No, as of 2023, no new FDA-approved indications have been granted since its initial approval in 1997.
-
What are the primary competitors to cefdinir? Amoxicillin-clavulanate and cefuroxime are primary competitors, with similar broad-spectrum activity.
-
Has cefdinir been subjected to resistance issues? Yes, increasing resistance among common pathogens like Streptococcus pneumoniae affects clinical utility, prompting trials against resistant strains.
-
Are extended-release formulations of cefdinir available? Several companies are testing extended-release versions, but none have received regulatory approval yet.
-
What is the outlook for cefdinir’s profitability? Patent expiration and generic competition limit profitability; growth will depend on formulation innovation and resistance trends.
References
[1] MarketWatch. (2023). "Cephalosporin market size and forecasts."
[2] FDA. (1997). Cefdinir approval documentation.
[3] GlobalData. (2022). "Antibiotics Market Report."
[4] ClinicalTrials.gov. (2023). "Ongoing cefdinir-related trials."
[5] IQVIA. (2022). "Antibiotics sales and market share analyses."
